Irvingia Gabonensis
Irvingia gabonensis
Also known as: African mango, Dika nut, Bush mango, Wild mango, Ogbono
Evidence Strength: MODERATE
This ingredient is classified as unclassified risk (GIRI score: 3.0/10). The classification is based on mechanistic and clinical evidence: irvingia gabonensis is thought to aid weight loss by affecting adipogenesis and….
Safety Profile
Common Adverse Effects
- Headache
- flatulence
- sleep disturbances
- dry mouth
- gastrointestinal discomfort
Serious Adverse Effects
- Allergic reactions
- liver dysfunction
- severe gastrointestinal distress
Contraindications
- Liver disease
- pregnancy
- breastfeeding
- hypersensitivity
- People taking Antidiabetic drugs
Interactions
| Drug / Nutrient | Interaction Mechanism | Warning |
|---|---|---|
| Antidiabetic drugs | potential additive effects — monitor blood glucose levels. Antihypertensive drugs: possible enhancement of effects — monitor blood pressure. Statins: potential interaction affecting lipid levels — clinical monitoring advised. | Monitor |
Evidence and Scientific Findings
Ingredient Overview
Biological and Chemical Classification
- Chemical Class
- Polyphenol
- Biological Class
- Plant extract
- Natural Source
- Irvingia gabonensis seeds
- Scientific Name
- Irvingia gabonensis
- Chemical Formula
- Not applicable
- CAS Number
- Not applicable
Mechanism of Action
Clinical Evidence of Effectiveness
| Indication | Evidence Level | Summary |
|---|---|---|
| General | Moderate | Several small-scale clinical trials have suggested that Irvingia gabonensis can contribute to weight loss and improve metabolic parameters. However, the studies often have limitations such as small sample sizes and short durations. While some trials report significant reductions in body weight and waist circumference, the overall quality of evidence is moderate, and further research is needed to confirm these findings. |
Pharmacokinetics
Recommended Dosage
| Condition / Use | Typical Dose |
|---|---|
| Weight loss | 150-300 mg twice daily. |
Dosage ranges are based on clinical studies and commonly used supplement formulations. Individual requirements may vary.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Irvingia gabonensis, commonly known as African mango, is a tree native to West Africa.
- Evidence consistency: High consistency across studies (100%)
- Irvingia gabonensis is generally considered safe for short-term use in healthy adults. However, caution is advised for individuals with liver conditions due to potential hepatotoxicity. Pregnant and breastfeeding women should avoid its use due to insufficient safety data. Regulatory agencies have not issued specific warnings, but users should consult healthcare providers before starting supplementation.
- USA/FDA — Approved
The available scientific evidence for Irvingia Gabonensis indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 06 მარ 2026, 12:01
Evidence Distribution
-
Observational / other LOW evidence YELLOWTechnological innovations in margarine production: Current trends and future perspectives on trans-fat removal and saturated fat replacement. ↗Bihola A et al.. Technological innovations in margarine production: Current trends and future perspectives on trans-fat removal and saturated fat replacement.. Compr Rev Food Sci Food Saf. 2025. PMID:39699296.PMID 39699296 ↗Journal Compr Rev Food Sci Food SafYear 2025Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39699296/
-
Observational / other LOW evidence YELLOWAntibacterial activities, PASS prediction and ADME analysis of phytochemicals from Curcubita moschata, Curcubita maxima, and Irvingia gabonensis: insights from in silico studies. ↗Abdul-Hammed M et al.. Antibacterial activities, PASS prediction and ADME analysis of phytochemicals from Curcubita moschata, Curcubita maxima, and Irvingia gabonensis: insights from in silico studies.. In Silico Pharmacol. 2024. PMID:39035102.PMID 39035102 ↗Journal In Silico PharmacolYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/39035102/
-
Animal study LOW evidence YELLOWAnti-diabetic, anti-pancreatic lipase, and anti-protein glycation potential of Irvingia gabonensis stem bark extracts: in vitro and in silico studies. ↗Omonkhua AA et al.. Anti-diabetic, anti-pancreatic lipase, and anti-protein glycation potential of Irvingia gabonensis stem bark extracts: in vitro and in silico studies.. In Silico Pharmacol. 2024. PMID:38751710.PMID 38751710 ↗Journal In Silico PharmacolYear 2024Study type Animal studyEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/38751710/
-
Observational / other LOW evidence YELLOWEvaluation of microstructure evolution and mechanical properties of Al-10Zn-1.63Si/Irvingia gabonensis particulates alloy composites. ↗Jeremiah Lekwuwa C et al.. Evaluation of microstructure evolution and mechanical properties of Al-10Zn-1.63Si/Irvingia gabonensis particulates alloy composites.. J Appl Biomater Funct Mater. 2024. PMID:38488249.PMID 38488249 ↗Journal J Appl Biomater Funct MaterYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/38488249/
-
Observational / other LOW evidence YELLOWIrvingia gabonensis baill. (African Mango): A comprehensive review of its ethnopharmacological significance, unveiling its long-standing history and therapeutic potential. ↗Hassan YR et al.. Irvingia gabonensis baill. (African Mango): A comprehensive review of its ethnopharmacological significance, unveiling its long-standing history and therapeutic potential.. J Ethnopharmacol. 2024. PMID:38395180.PMID 38395180 ↗Journal J EthnopharmacolYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/38395180/
-
Observational / other LOW evidence YELLOWA mechanistic exploration of the metabolome of African mango seeds and its potential to alleviate cognitive impairment induced by high-fat/high-carbohydrate diets: Involvement… ↗Hassan YR et al.. A mechanistic exploration of the metabolome of African mango seeds and its potential to alleviate cognitive impairment induced by high-fat/high-carbohydrate diets: Involvement of PI3K/AKT/GSK-3u03b2/CREB, PERK/CHOP/Bcl-2, and AMPK/SIRT-1/mTOR Axes.. J Ethnopharmacol. 2024. PMID:38218500.PMID 38218500 ↗Journal J EthnopharmacolYear 2024Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/38218500/
-
Observational / other LOW evidence YELLOWA comprehensive review on clinically proven medicinal plants in the treatment of overweight and obesity, with mechanistic insights. ↗Aziz MA et al.. A comprehensive review on clinically proven medicinal plants in the treatment of overweight and obesity, with mechanistic insights.. Heliyon. 2023. PMID:36816319.PMID 36816319 ↗Journal HeliyonYear 2023Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/36816319/
-
Observational / other LOW evidence YELLOWFlavonoid glycosides and ellagic acid cognates from defatted African mango (Irvingia gabonensis) seed kernel. ↗Zulfiqar F et al.. Flavonoid glycosides and ellagic acid cognates from defatted African mango (Irvingia gabonensis) seed kernel.. Nat Prod Res. 2023. PMID:36318869.PMID 36318869 ↗Journal Nat Prod ResYear 2023Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/36318869/
-
Observational / other LOW evidence YELLOWDietary supplements for obesity. ↗Bonetti G et al.. Dietary supplements for obesity.. J Prev Med Hyg. 2022. PMID:36479472.PMID 36479472 ↗Journal J Prev Med HygYear 2022Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/36479472/
-
Observational / other LOW evidence YELLOWEffects of Irvingia gabonensis Extract on Metabolism, Antioxidants, Adipocytokines, Telomere Length, and Aerobic Capacity in Overweight/Obese Individuals. ↗Nonsa-Ard R et al.. Effects of Irvingia gabonensis Extract on Metabolism, Antioxidants, Adipocytokines, Telomere Length, and Aerobic Capacity in Overweight/Obese Individuals.. Nutrients. 2022. PMID:36364907.PMID 36364907 ↗Journal NutrientsYear 2022Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/36364907/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Irvingia Gabonensis. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Irvingia Gabonensis
A score of 3.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
1 jurisdiction has active restrictions or advisories. Regulatory signals are recorded as Safety Signals and raise the S component.
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.